A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated May 9, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Recruiting
  2. Start date: Jan 31, 2024 to Apr 16, 2024v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 31, 2023 to Jan 31, 2024
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, prospective study to assess the efficacy and safety of acalabrutinib combined with obinutuzumab in subjects with previously untreated chronic lymphocytic leukemia.
Trial Details
NCT Number NCT05950997
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Chronic Lymphocytic Leukemia
Related terms Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 89 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov